BRIEF-Assembly Biosciences, Door Pharmaceuticals Sign Collaboration, Option Agreement To Develop Novel Class Of HBV Core Protein Modulators
* ASSEMBLY BIOSCIENCES AND DOOR PHARMACEUTICALS SIGN COLLABORATION AND OPTION AGREEMENT TO DEVELOP A NOVEL CLASS OF HBV CORE PROTEIN MODULATORS Source text for Eikon: Further company coverage: